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Available online 21 December 2016Among the identiﬁed barriers to HPV vaccination is the concern that women may compensate for their reduced
susceptibility to cervical cancers by reducing cervical cancer screening. This exploratory study examined the re-
lationship between cervical cancer screening rates and HPV vaccination. We conducted a cross-sectional survey
using a convenience sample of women aged 21–35 attending a local minority health fair in July 2015. Data were
analyzed in 2015–2016. Outcomes assessed were: receiving a Pap test within the last three years, awareness and
comfort with current Pap test recommendations, and knowledge regarding the purpose of a Pap test. A total of
291 women were included in the analyses. Mean age was 28.5 years and 62% were non-Hispanic black. 84%
had received a Pap test in the last three years and 33% had received at least one HPV vaccine. Logistic regression
results showed that women who had been vaccinated did not have lower odds of having a Pap test in the past
three years (OR = 1.32; 95% CI = 0.66–2.65). In an adjusted regression model controlling for age and race, vac-
cinatedwomenwere signiﬁcantly more likely to have had a Pap test (AOR= 3.06; 95% CI= 1.37–6.83). Yet only
26% of women knew the purpose of a Pap test and the proportion who answered correctly was higher among
non-Hispanic white women. Women who have been vaccinated for HPV are more likely to have been screened
for cervical cancer. These results suggest areas formore robust studies examining pro-health attitudes, behaviors,
and communication regarding vaccination and preventive screening.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Risk compensation1. Introduction
HPV is the most common sexually transmitted infection (STI) in the
U.S. (Centers for Disease Control and Prevention, 2014) Infection with
HPV can cause serious health issues including genital warts and cancers
of the cervix, anus, and oropharynx, among others (National Institutes
of Health, 2015). At the time of this study there were three different
HPV vaccines licensed by the U.S. Food and Drug Administration and
at that time a series of three doses was recommended for all of the vac-
cines (Markowitz et al., 2014). However, the CDC recently updated their@mofﬁtt.org (M.L. Kasting),
llinger),
.arizona.edu (N.W. Stupiansky),
s and Behavior, 12902Magnolia
d Zuckerman College of Public
, AZ USA.
. This is an open access article underrecommendations so that a child can receive a two-dose series of the 9-
valent HPV vaccine, 6–12 months apart, as long as the ﬁrst dose is ad-
ministered before age 15. For those who initiate the series at age 15 or
older, the three-dose series is still recommended (CDC recommends
only two HPV shots for younger adolescents [press release]. Atlanta,
GA, October 20, 2016, 2016). Detailed information about all of the vac-
cines can be found in Petrosky et al. (2015). The Advisory Committee
on Immunization Practices (ACIP) recommends routine HPV vaccina-
tion for boys and girls age 11 or 12 and catch up vaccination for
women up through age 26, all men up through age 21, and for men
who have sex with men up to age 26 (Markowitz et al., 2014).
HPV vaccination rates in the U.S. remain lower than desired (Stokley
et al., 2014). In 2015, only 41.9% of all adolescent girls and 28.1% of all
adolescent boys between the ages of 13 and 17 completed the three-
dose series (Reagan-Steiner et al., 2016). There are several reported bar-
riers to HPV vaccination but one that has received particular attention
especially in the media is the idea that receiving the HPV vaccine will
lead a person to engage in riskier behaviors. This is known as Risk Com-
pensation Theory and has been widely studied in the context of sexualthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
170 M.L. Kasting et al. / Preventive Medicine Reports 5 (2017) 169–174behaviors (Wilde, 1982;Wilde, 1998; Kasting et al., 2016). Concomitant
with risk compensation is the additional concern that womenwhohave
received the HPV vaccine may compensate for their reduced suscepti-
bility to cervical cancers by reducing their participation in cervical can-
cer screening (Tiro et al., 2008; Kollar and Kahn, 2008; Pollitt, 2005;
Juraskova et al., 2011).
Compared to sexual risk compensation, there has been less research
conducted on cervical cancer screening behavior post-HPV vaccination,
particularly regarding knowledge and uptake among minority women.
Studies have shown that non-Hispanic black women have higher inci-
dence of cervical cancer (Ward et al., 2004) and are less likely to get
screened (Moser et al., 2009) than their white counterparts. One study
by Robb et al. in England found cervical cancer screening awareness
was lower in ethnic minorities. However, the Robb study did not assess
knowledge, and is not representative of minorities in the U.S. (Robb et
al., 2010) Furthermore, the idea of risk compensation was developed
for use in the context of seat belt laws and risky driving techniques
and may not be relevant when it comes to vaccination and other health
risk behaviors. For example, one study found that health-protective be-
haviors such as diet, exercise, and contraception use clustered together
and those who engaged in one pro-health behavior were more likely to
engage in another (Fortenberry et al., 1997).
Women are generally unaware of screening guidelines (Mather et
al., 2012) which have changed four times in the last 30 years
(American Cancer Society, 2014). The current CDC recommendations
for average risk women state that women should be screened with a
Papanicolaou (Pap) test every three years from age 21 to 29. That
screening period can be extended to ﬁve years from age 30 to 65 if the
woman has an HPV DNA co-test along with the Pap test and both are
negative. Screening is not recommended after age 65 (Centers for
Disease Control and Prevention, 2012). Some studies have found that
Pap screening was either positively associated with vaccination or no
association was found (Williams et al., 2013; Anhang Price et al.,
2011; Caskey et al., 2009). Using a national dataset, one of these studies
found that a lower percentage of women who were not vaccinated re-
ported having a recent Pap test as compared to vaccinated women
(81.0% vs. 90.5%) (Sauer et al., 2015). The ﬁndings of the limited re-
search to date suggest that HPV vaccinationmay not have a negative ef-
fect on women's participation in cervical cancer screening. However,
this relationship is not yet fully understood, particularlywithinminority
populations. There also is a need for ongoing research regarding
women's knowledge and beliefs about screening, particularly given
the potential for future changes in screening guidelines to HPV DNA
testing only, such as those being implemented in 2017 in Australia
and 2018 in New Zealand (Smith et al., 2016; Lew et al., 2016). One re-
cent study examining a largely minority population did also ﬁnd posi-
tive associations between HPV vaccination and cervical cancer
screening (Boone et al., 2016). However, these results, obtained from
medical records, were not able to examinewomen's knowledge and be-
liefs regarding vaccination and screening in order to illuminate the rela-
tionship between the two.
The present study examined the relationship between HPV vaccina-
tion and Pap testing using responses to an exploratory cross-sectional
survey of mostlyminority women.We used both quantitative and qual-
itative methodology to: 1) examine if cervical cancer screening rates
differed between thosewhohad andhad not been vaccinated and 2) as-
sess if women understood the purpose of, and current recommenda-
tions for, Pap testing.
2. Methods
2.1. Participants
All study procedures were approved by the Indiana University IRB.
The research was conducted in July 2015, analyzed in 2015 and 2016,
and targetedwomen ages 21 to 35 years who attended the 46th AnnualIndiana Black Expo Health Fair in Indianapolis. This age range was cho-
sen because these women are eligible for screening and were all
26 years of age or younger when the ﬁrst HPV vaccine was licensed in
2006. The Annual Indiana Black Expo is one of the nation's largest cul-
tural events for African-Americans and draws an estimated 40,000 at-
tendees from across Indiana and surrounding states. The minority
health fair is a component offered at this event.
Exclusion criteria includedwomenwith a hysterectomy andwomen
who received the vaccine less than three years prior to the survey be-
cause therewould not be sufﬁcient time to assess their post-vaccination
screening behaviors. A total of 317 women started the survey; 291 of
them were included in analysis after excluding those with a history of
hysterectomy (n = 8), those who were vaccinated for HPV less than
three years ago (n= 13), and those who started but did not complete
the survey (n = 5). It was not possible to determine the declination
rate due to the nature of the study setting.
2.2. Measures
Theweb-based surveywas computer-administered. Questionswere
modeled after relevant items from the National Health Interview Survey
(NHIS), a population survey administered by the CDC. The questions
assessed if participants received the HPV vaccine, how many shots
they received, and at what age. We also assessed when participants
had their last Pap test.We then expanded on the NHIS questions by ask-
ing if participants were aware of the new cervical cancer screening rec-
ommendations and how comfortable they were with the frequency of
the screenings in the new recommendations. Comfort with screening
recommendationswas assessedwith a Likert-type variable. Participants
were told current screening recommendations and then asked “How
comfortable are you with this new screening recommendation?” Re-
sponses were on a ﬁve-point scale ranging from very uncomfortable
to very comfortable. We also asked open-ended questions to assess if
participants knew the purpose of a Pap test by asking, “What is the pur-
pose of a Pap smear or Pap test?”
2.3. Analyses
2.3.1. Quantitative analysis
The main outcome assessed was whether the women were up-to-
date on cervical cancer screenings. Women who indicated they had
been screened within the last three years were considered current;
women who indicated their last screening was over three years ago or
had never been screened were considered not current. We compared
the demographic characteristics of women who were current with
womenwhowere not current using bivariate analyses.Multivariable lo-
gistic regression assessed the association of HPV vaccination status and
screening, adjusting for the effects of the demographic variables that
were found to be independently signiﬁcantly associated with screening
such as age and race. In order to explain the interaction between age
and vaccination status, stratiﬁed logistic regression models were con-
ducted separately for each age group in ﬁve-year increments. Addition-
ally, we assessed women's knowledge and comfort with cervical cancer
screening guidelines using frequency tables and regression analyses. All
quantitative analyses were performed using SPSS v. 22.0 (IBM Corp.,
Armonk, NY, USA). P b 0.05 was considered statistically signiﬁcant.
2.3.2. Qualitative analysis
The survey included an open-ended question (“What is the purpose
of a Pap smear or Pap test?”) which was analyzed using inductive con-
tent analysis (Elo and Kyngäs, 2008). Responses to questions were
coded independently by two investigators (MLK & SW) and assessed
to identify meaningful themes. The coded responses were reviewed
and areas of disagreement were resolved through discussion. Partici-
pants were also assessed onwhether they correctly answered the ques-
tion. In order to consider the response to the question correct, the
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cells of the cervix. If a participant did not mention the cervix, or she
indicated the test also checks for STIs, she was marked as answering
the question partially correct. All other answers were considered
incorrect. In order to assess racial disparities in knowledge regarding
cervical cancer screening, we examined differences in answers between
non-Hispanic blacks and non-Hispanic whites. For these questions
only, we excluded womenwho indicated that their race was “Hispanic”
(n=14), “Asian” (n=14), “other” (n=4), and “multiracial” (n=11)
because the number of respondents were relatively small and
heterogeneous.
3. Results
3.1. Sample description
A full description of the respondents, including differences by
screening status, is shown in Table 1. The respondents' ages ranged
from 21 to 35 (m = 28.5, SD = 4.7). Race was assessed by self-report
and nearly two-thirds of the respondents (62.5%, n= 182) were non-
Hispanic black, 22.7% (n = 66) were non-Hispanic white, and 14.8%
(n = 43) were Hispanic, other, or multiracial. A majority of the
women in the study received a Pap test in the last three years (84.2%,
n= 245), and 33% (n= 97) had received at least one HPV vaccination.
There were demographic differences in the bivariate comparisonsTable 1
Sample description by cervical cancer screening status (current vs. not current).
Total
sample
(n = 291)
Current
(n = 245)
Not current
(n = 46)
p-value
Mean age (continuous) 28.5 29.1 25.3 b0.001
Age (categorical) n (%) b0.001
21–25 years old 99 (34.0) 69 (28.2) 30 (65.2)
26–30 years old 82 (28.2) 73 (29.8) 9 (19.6)
31–35 years old 110 (37.8) 103 (42.0) 7 (15.2)
Race n (%) 0.004
Non-Hispanic white 66 (22.7) 56 (22.9) 10 (21.7)
Non-Hispanic black 182 (62.5) 160 (65.3) 22 (47.8)
Othera 43 (14.8) 29 (11.8) 14 (30.4)
Education n (%) 0.112
Some high school/high
school graduate/GED
35 (12.0) 27 (11.0) 8 (17.4)
Some college/trade
school/4-year degree
154 (52.9) 136 (55.5) 18 (39.1)
Some post-grad/graduate
degree
102 (35.1) 82 (33.5) 20 (43.5)
HPV vaccine status n (%) 0.497
Received N = 1 dose 97 (33.3) 84 (34.3) 13 (28.3)
Never received HPV vaccine
or unsure
194 (66.7) 161 (65.7) 33 (71.7)
Purpose of a Pap test n (%) 0.317
Incorrect 104 (35.7) 84 (34.3) 20 (43.5)
Partially correct 110 (37.8) 97 (39.6) 13 (28.3)
Correct 77 (26.5) 64 (26.1) 13 (28.3)
Pap recommendation
awareness n (%)
b0.001
Aware 132 (45.5) 122 (50.0) 10 (21.7)
Unaware 158 (54.5) 122 (50.0) 36 (78.3)
Guideline comfort n (%) 0.005
Very uncomfortable 63 (21.8) 59 (24.2) 4 (8.9)
Somewhat uncomfortable 61 (21.1) 52 (21.3) 9 (20.0)
Neither comfortable nor
uncomfortable
51 (17.6) 39 (16.0) 12 (26.7)
Somewhat comfortable 39 (13.5) 27 (11.1) 12 (26.7)
Very comfortable 75 (26.0) 67 (27.5) 8 (17.8)
Boldface indicates statistical signiﬁcance (p b 0.05) between those who were current and
those who were not current for a Pap test.
Abbreviations: GED, General Educational Development; HPV, Human Papillomavirus; Pap,
Papanicolaou.
a “Other” category includes people who indicated “other” for their race, people who
indicated multiple races, and Hispanics.between the participants whowere current on their Pap testing as com-
pared to those whowere not. Those whowere current on their cervical
cancer screening were more likely to be younger (p b 0.001) and
Hispanic, other, or multiracial (p= 0.004).
3.2. Quantitative results
3.2.1. Association between HPV vaccination and cervical cancer screening
In bivariate logistic regression, women who indicated they had re-
ceived at least one HPV vaccine dose in the series were not less likely
to have received a Pap test when compared to unvaccinated women
(OR = 1.32; 95% CI = 0.66–2.65). In contrast to the prediction of risk-
compensation theory, multivariable logistic regression, controlling for
age and race, showed that vaccinated women were actually more likely
to obtain cervical cancer screening than their non-vaccinated counter-
parts (AOR = 3.06; 95% CI = 1.37–6.83). For all regression analyses,
see Table 2.
An interaction analysis was performed to assess if agewas the driver
in the relationship between vaccination status and Pap testing. The in-
teraction between age and vaccination status was then entered into
the model and was statistically signiﬁcant (OR = 1.62; 95% CI = 1.05–
2.50; p = 0.003). Stratiﬁed logistic regression models indicated that
the relationship between vaccination status and cervical cancer screen-
ing frequency was not signiﬁcant for 21 to 25 year olds (34%; n= 99)
while controlling for race (OR = 2.0; 95% CI = 0.8–5.0). For the 26 to
30 (28%; n = 82) and 31 to 35 (38%; n = 110) age groups, of the
women who were overdue for Pap testing (n= 9 and 7 respectively),
none had been vaccinated for HPV. We then performed a Fisher's
exact test and found that the relationship between vaccination status
and Pap testing was signiﬁcant for the middle age group (p = 0.03)
but was not signiﬁcant for the youngest or oldest age groups (p =
0.13 and 0.59, respectively).
3.2.2. Beliefs about post-vaccination screening frequency
When asked if vaccinatedwomen should get screened less frequent-
ly than unvaccinated women, 17% (n= 50) incorrectly said “yes,” 68%
(n = 198) said “no,” and 15% (n = 43) said they did not know.
Women who answered the question correctly were not more likely to
have had a Pap test in the last three years than women who answered
the question incorrectly (OR=1.18; 95% CI= 0.48–2.92). However, re-
sponse patterns varied by HPV vaccination status, and women who an-
swered the question correctly were more likely to be vaccinated than
women who answered it incorrectly (OR = 2.77; 95% CI = 1.31–
5.85). The accuracy of the responses to the question about whetherTable 2
Regression analyses assessing the receipt of a pap test in the last three years.
Bivariate odds ratio
(95% CI)
Multivariable odds
ratio (95% CI)
Ever received HPV vaccine
No Ref Ref
Yes 1.32(0.66–2.65) 3.06 (1.37–6.83)
Race
Non-Hispanic white Ref Ref
Non-Hispanic black 1.30(0.58–2.91) 0.94 (0.39–2.27)
Other 0.37(0.15–0.94) 0.30 (0.11–0.82)
Age (continuous) 1.21(1.12–1.31) 1.26 (1.15–1.38)
Educationa
Some high school/high school
graduate/GED (ref)
Ref
Some college/trade school/4-year
degree
2.24(0.88–5.67)
Some post-grad/graduate degree 1.22(0.48–3.07)
Boldface indicates statistical signiﬁcance (p b 0.05).
Abbreviations: GED, General Educational Development; HPV, Human Papillomavirus; Pap,
Papanicolaou.
a These variables were not signiﬁcant in the bivariate analysis and were subsequently
excluded from multivariable regression model.
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ferent frequency than non-vaccinated women also varied by race; par-
ticipants who answered incorrectly were more likely to be non-
Hispanic black than participants who answered correctly (OR = 3.19;
95% CI = 1.27–7.97).
When asked how often a woman should get a Pap test if she has
never had cervical cancer or an abnormal Pap test, 64% (n=187) incor-
rectly responded they thought she should get screened every year.
There were variations by race; those who answered incorrectly had
double the odds of being be non-Hispanic black (OR = 2.0; 95% CI =
1.11–3.58).Womenwere then told the current recommendation for av-
erage risk women is every three years and were asked if they were
aware of this recommendation. Almost half (45.3%, n= 132) indicated
they were aware of the recommendation. Of the women who were
aware of the current recommendation, 53% (n = 70) indicated that
they knew the recommendation was every three years, but still stated
the women should get screened every year. When asked on a ﬁve-
point scale how comfortable they were with the new screening recom-
mendations, 43% (n = 124) indicated they were either very or some-
what uncomfortable, 40% (n= 114) reported they were either very or
somewhat comfortable, and 18% (n= 51) indicated they were neither
comfortable nor uncomfortable.3.3. Qualitative results
At the beginning of the survey, prior to deﬁning the term “Pap
smear.” respondents were asked “What is the purpose of a Pap
smear or Pap test?” Almost half (49%, n = 143) stated that a Pap
test checks for cancer, although not all participants knew it tested
speciﬁcally for cervical cancer. Additionally, 20% (n = 57) stated it
checked for abnormal or precancerous cells and 41% (n = 119)
knew that a Pap test checked the cervix. Some (29%; n = 85)
were vague in their answers (i.e. “to check for abnormalities”) sug-
gesting they did not fully understand the purpose of a Pap test and
9% (n = 25) indicated that a Pap test checked for STIs in general
and an additional 9% of women (n= 25) stated the Pap test checked
for “disease” but did not speciﬁcally say what disease. Some partici-
pants thought a Pap test evaluated other body parts including the
ovaries, uterus, breasts, and generic terms such as “organs” and
“down there.”
We examined whether responses from the participants regarding
the purpose of a Pap testwere correct or incorrect. Just over one quarter
of women (26%; n=77) answered correctly, 38% of women (n=110)
were partially correct, and 36% (n=104) answered incorrectly. Correct
answers varied by race and participants who answered incorrectly had
more than four times the odds of being non-Hispanic black as compared
to those who answered correctly (OR = 4.20; 95% CI = 2.00–8.81;
p b 0.001). A breakdown of answers by race/ethnicity can be found in
Table 3.Table 3
Answers to “What is the purpose of a Pap smear or Pap test?” by race/ethnicity.
Purpose of a Pap
Overall
(n = 248)
Non-Hispanic white
(n = 66)
Non-Hispanic black
(n = 182)
Correct n (%) 64 (25.8) 29 (43.9) 35 (19.2)
Partially correct n (%) 93 (37.5) 22 (33.3) 71 (39.0)
Incorrect n (%) 91 (36.7) 15 (22.7) 76 (41.8)
Abbreviations: Pap, Papanicolaou; STD, Sexually Transmitted Disease.4. Discussion
4.1. Behaviors and beliefs around vaccination and cervical cancer screening
We examined a convenience sample of mostly non-Hispanic black
women to compare cervical cancer screening practices between HPV
vaccinated and unvaccinated women. We also explored knowledge re-
garding the purpose of a Pap test, current screening recommendations,
and level of comfort with the current screening recommendations. In
contrast to the prediction of risk-compensation theory, the results sug-
gest no relationship between vaccination status and subsequent cervical
cancer screening behaviors. Moreover, when the relationship is exam-
ined controlling for age and race of the respondent, we found that
womenwhohad been vaccinated had a three times greater odds of hav-
ing been screened for cervical cancer within the last three years. This is
consistent with recent research that used a national sample and found
uptake of Pap testing was lower among those who had not initiated
the HPV vaccination series (Sauer et al., 2015). It is also consistent
with other health behavior literature that has demonstrated that pro-
health behaviors cluster and a personwhomakes the decision to engage
in one protective health behavior (e.g. getting the HPV vaccine) is more
likely to engage in another (e.g. getting screened for cervical cancer)
(Fortenberry et al., 1997).
Most women knew that HPV-vaccinated women are recommended
to obtain cervical cancer screening at the same frequency as unvaccinat-
ed women. Results varied by vaccination status but did not vary by
whether the women were current for cervical cancer screenings. The
majority of women thought an average-risk woman should get
screened every year, even though 45% of women claimed to know
that the recommendation was every three years. This might be because
current practice has not caught up with recommendations, the partici-
pants did not like admitting they were unaware of current screening
recommendations, or it may be indicative of how uncomfortable
women may be with the screening recommendations. More women
were uncomfortable than comfortable with the current screening rec-
ommendations, suggesting that discomfort as well as lack of awareness
may be a signiﬁcant problem. While adherence to cervical cancer
screening guidelines is important in terms of cost-effectiveness
(Schiffman et al., 2011), provider communication and education is es-
sential for patient-centered care (Levinson et al., 2010). This could be
an area for a future intervention targeted at reminding physicians to ed-
ucate their patients on the purpose of Pap tests and the current cervical
cancer screening recommendations as well as for a broader public
health campaign aimed at increasing knowledge around current cervi-
cal cancer screening guidelines.
4.2. Cervical cancer screening beliefs and understanding
Most women knew that Pap testing checked for cancer or abnormal
cells but less than half knew it was checking the cervix. Additionally,Example quotes
“For early detection of cancerous cells in the cervix.”
“Screening test which detects pre-cancerous or cancerous cervical cells.”
“Screening for cervical cancer.”
“The check for any abnormalities and to screen for cervical cancer as well as STDs.”
“To ensure there are no abnormalities that may lead to ovarian or cervical cancer.”
“To determine if you possibly have breast cancer.”
“Check for irregular uterine cells.”
“To check for STDs and make sure everything is good with female organs.”
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Pap test and some thought they were also being checked for uterine or
ovarian cancer. Only one-fourth of the sample correctly answered the
question stating a Pap test checked for cervical cancer only.
4.3. Racial disparities in cervical cancer knowledge
There were racial disparities observed in questions concerning
knowledge of cervical cancer screening. Non-Hispanic black partici-
pants were less likely to be aware of current screening recommenda-
tions. They were also less likely to correctly identify the purpose of a
Pap smear which means that not only are non-Hispanic black women
substantially less aware of screening recommendations, but they also
lack a fundamental knowledge regarding the purpose of a Pap test.
This could be due to differences in education between the two groups
but also indicates there is signiﬁcant room for improvement in educat-
ing particularly minority women regarding the purpose of and guide-
lines for cervical cancer screening. It is important for healthcare
providers to know about these differences in order to target minority
women for educational opportunities and tailor their education and
screening messages that would be sensitive to the needs of different
populations.
4.4. Limitations
This study gathered survey data from a convenience sample, thus
thewomen in the samplemay not be representative of the general pop-
ulation. However, our survey results were consistent with those from a
previous national study (Sauer et al., 2015). There may also be a selec-
tion bias, with greater participation of with pro-health attitudes. The
measures for receipt of HPV vaccination and Pap screening were both
self-reported and are subject to recall bias and reporting errors.
5. Conclusions
The current study found that cervical cancer screening practices be-
tween vaccinated and unvaccinated participants were not different
overall. In fact, contrary to risk-compensation theory, there was a posi-
tive relationship between vaccination and screening when adjusted for
age and race. Rather than supporting risk compensation, this set of ﬁnd-
ings adds credibility to the hypothesis that higher screening rates
among vaccinated women may be related to access to healthcare and
pro-health attitudes. The ﬁndings suggest this is an area for future re-
searchusing stronger study designs in order tomake stronger, causal ar-
guments about the relationship of HPV vaccination to cervical cancer
screening. Findings from this study may inform future interventions
with stronger study designs aimed at tailoring messages for patients,
standardizing education for providers, or both. The results of such stud-
ies may disentangle the effects of both of these approaches in order to
effectively assist healthcare providers in communicating effectively
with their patients about HPV vaccination and cervical cancer screening.
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